2 terminated, 1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow EGFR L858R: new trials by email Literature Review of EGFR L858R trials Research Report on EGFR L858R
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases EDB-102 - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 15 | 2026-02-10 | 2026-03-10 |
| A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) Plasma ctDNA, FFPE blocks - Non Small Cell Lung Cancer, EGFR Activating Mutation | Not applicable | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 300 | 2024-01-22 | 2024-03-08 |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Patritumab Deruxtecan, Platinum-based chemotherapy - Nonsquamous Non-small Cell Lung Cancer, EGFR L858R | Phase 3 | Active not recruiting | Daiichi Sankyo | 586 | 2022-07-08 | 2026-08-27 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation Bevacizumab, Icotinib - Carcinoma, Non-Small-Cell Lung, Bevacizumab | Phase 2 | Completed | Tianjin Medical University Cancer Institute and Hospital | 35 | 2022-01-30 | 2026-02-24 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
Carcinoma, Non-Small-Cell Lung (5) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Nerve Tissue (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Bronchial Diseases (2) · Neoplasms, Glandular and Epithelial (2)
osimertinib (2) · Bevacizumab (1) · Carboplatin (1) · Pemetrexed (1) · Platinum Compounds (1) · icotinib (1) · patritumab deruxtecan (1)
Blueprint Medicines Corporation (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Daiichi Sankyo (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Tianjin Medical University Cancer Institute and Hospital (1)
France (3) · United States (3) · Canada (2) · China (2) · Japan (2) · Netherlands (2) · Singapore (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Germany (1)
Ning Li, PhD (1) · Zhanyu Pan (1)
2023 (1)